CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma
NCT00044018
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
102
Enrollment
INDUSTRY
Sponsor class
Conditions
Multiple Myeloma
Interventions
DRUG:
CDC-501
Sponsor
Celgene